Related Experiment Videos
10 questions about using apomorphine for Parkinson disease
1University of Texas Southwestern Medical Center, Dallas, TX 75390-9036, USA. Richard.Dewey@UTSouthwestern.edu
The Neurologist
|April 30, 2005
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature.
Clinical parkinsonism & related disorders·2023
Severity of depressive and motor symptoms impacts quality of life in Parkinson's disease patients at an academic movement clinic: A cross-sectional study.
Clinical parkinsonism & related disorders·2023
APDM gait and balance measures fail to predict symptom progression rate in Parkinson's disease.
Frontiers in neurology·2022
Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease.
Annals of neurology·2022
Time over drug in pediatric status epilepticus: A prospective observational study.
Epilepsy & behavior : E&B·2026
Drug-induced autophagic myopathies: Exploring pathophysiology with immunolabelling and proteomics.
Journal of neuropathology and experimental neurology·2026
Concordance between plasma biomarkers of phosphorylated tau and tau-PET: A narrative review.
Journal of Alzheimer's disease : JAD·2026
Evaluation of haloperidol decanoate initiation dosing in inpatients with serious mental illness.
The mental health clinician·2026
Use of antipsychotic medication with weight-inducing potential in first-episode psychosis.
Frontiers in psychiatry·2026